InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,567.19
(
1.06%
)
US TECH 100
19,828.00
(
0.95%
)
Dow Jones
39,375.87
(
0.17%
)
Brent Oil
86.78
(
0.00%
)
Bitcoin
57,532.32
(
-1.32%
)
Post# of 2342610
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Jose Chavez

Send PM Follow Ignore
Followers 5
Posts 2568
Boards Moderated 0
Alias Born 11/03/2019

Jose Chavez

Re: None

Thursday, 05/19/2022 11:55:16 AM

Thursday, May 19, 2022 11:55:16 AM

Post# of 2342610
$ATRX Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Jean Buteau, PhD., to the Company’s Scientific Advisory Board. Dr. Buteau, a published scientist, and award-winning pioneer in the field of diabetes, will lend his expertise and oversight to help advance Adhera’s pipeline, including MLR-1023, the Company’s Phase 2-ready drug candidate as a novel therapeutic for treating Type 1 diabetes (T1D).
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up